Table 2.

Therapeutical agents with action based on prevention of Aβ-containing pathological complexes formation.

Therapeutical Agent (Class of Agents)	Potential Function	Reference
Aducanumab (specific antibodies) and other agents preventing formation of Aβ fibrils formation	Prevention of Aβ assemblage into cytotoxic fibrils	[113]
Synthetic and natural peptides that may block amyloid–amyloid binding	Interaction conditioned by the similarity to the hydrophobic domains of Aβ	[117]
Small molecules able to inhibit Aβ misfolding and enhance its clearance (LS4, for example)	Specifically binding to different soluble forms of Aβ	[120]
CPO-Aβ17–21 peptide	Blocking the ability of APOE to initiate Aβ oligomerization	[122]
Cyclic peptide cG8	TTR-mimetic peptide comprising its Aβ-binding domain	[124]
Huperzine A and other ABAD blocking compounds	ABAD inhibition reduces Aβ-induced mitochondrial dysfunction	[127]
GAPDH–Aβ complex inhibitors	Blocking the formation of the GAPDH–Aβ complex and reduction of its cytotoxicity	[94,138]
Chaperone synthesis inducers	Newly synthesized chaperones block the formation of Aβ complexes with other proteins	[131,136,137]